Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

Signaling driven by hepatocyte growth factor (HGF) and MET receptor facilitates
conspicuous biological responses such as epithelial cell migration, 3‐D morphogenesis …

The Met receptor tyrosine kinase (RTK) is an attractive oncology therapeutic target. Met and
its ligand, HGF, play a central role in signaling pathways that are exploited during the …

Background Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which
also has an effect on the tumour immune microenvironment by decreasing regulatory T cells …

Abstract Background Sunitinib malate (SUTENT®) is an oral, multitargeted tyrosine kinase
inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib …

Decorin, a member of the small leucine-rich proteoglycan gene family, impedes tumor cell
growth by down-regulating the epidermal growth factor receptor. Decorin has a complex …

Hepatocyte growth factor (HGF) is a pleiotropic cytokine that has been extensively studied
over several decades, but was only recently recognized as a key player in mediating …

Proteases known as sheddases cleave the extracellular domains of their substrates from the
cell surface. The A Disintegrin and Metalloproteinases ADAM10 and ADAM17 are among …

Cellular senescence is a process by which cells enter a state of permanent cell cycle arrest.
It is commonly believed to underlie organismal aging and age-associated diseases …

Gliomas are the most frequent type of tumor in the central nervous system, which exhibit
properties that make their treatment difficult, such as cellular infiltration, heterogeneity, and …